1.58
price up icon1.28%   0.02
 
loading
Macrogenics Inc stock is traded at $1.58, with a volume of 1.05M. It is up +1.28% in the last 24 hours and up +25.40% over the past month. Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.56
Open:
$1.49
24h Volume:
1.05M
Relative Volume:
0.89
Market Cap:
$99.68M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.00
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-7.60%
1M Performance:
+25.40%
6M Performance:
-47.33%
1Y Performance:
-60.50%
1-Day Range:
Value
$1.49
$1.62
1-Week Range:
Value
$1.47
$1.76
52-Week Range:
Value
$0.9897
$5.10

Macrogenics Inc Stock (MGNX) Company Profile

Name
Name
Macrogenics Inc
Name
Phone
301-251-5172
Name
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Name
Employee
341
Name
Twitter
@macrogenics
Name
Next Earnings Date
2025-03-07
Name
Latest SEC Filings
Name
MGNX's Discussions on Twitter

Compare MGNX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MGNX
Macrogenics Inc
1.58 98.42M 139.77M -97.62M -61.71M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-07-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-01-24 Downgrade BTIG Research Buy → Neutral
Jul-31-24 Downgrade B. Riley Securities Buy → Neutral
Jul-31-24 Downgrade Guggenheim Buy → Neutral
May-10-24 Downgrade BMO Capital Markets Outperform → Market Perform
May-10-24 Downgrade Stifel Buy → Hold
May-10-24 Downgrade TD Cowen Buy → Hold
Apr-26-24 Initiated B. Riley Securities Buy
Apr-09-24 Upgrade TD Cowen Hold → Buy
Mar-04-24 Reiterated BTIG Research Buy
Feb-14-24 Downgrade H.C. Wainwright Buy → Neutral
Dec-20-23 Upgrade Citigroup Neutral → Buy
Nov-07-23 Upgrade Guggenheim Neutral → Buy
Mar-17-23 Downgrade Guggenheim Buy → Neutral
Nov-22-22 Downgrade Cowen Outperform → Market Perform
Nov-14-22 Upgrade BMO Capital Markets Market Perform → Outperform
Jul-18-22 Downgrade SMBC Nikko Outperform → Neutral
Jul-11-22 Downgrade BMO Capital Markets Outperform → Market Perform
May-04-22 Downgrade Guggenheim Buy → Neutral
Feb-28-22 Upgrade Citigroup Neutral → Buy
Feb-11-22 Initiated BMO Capital Markets Outperform
Feb-04-22 Initiated SMBC Nikko Outperform
Nov-17-21 Resumed Guggenheim Buy
Oct-19-21 Initiated JMP Securities Mkt Outperform
Oct-15-21 Resumed BTIG Research Buy
Apr-26-21 Resumed Credit Suisse Outperform
Mar-12-21 Upgrade Barclays Underweight → Overweight
Dec-22-20 Resumed H.C. Wainwright Buy
Aug-03-20 Downgrade Citigroup Buy → Neutral
Jun-01-20 Upgrade Guggenheim Neutral → Buy
May-26-20 Reiterated H.C. Wainwright Buy
Mar-04-20 Initiated Barclays Underweight
Dec-19-19 Initiated Cantor Fitzgerald Overweight
Dec-18-19 Initiated Cantor Fitzgerald Overweight
Nov-21-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-20-19 Resumed Guggenheim Neutral
May-03-19 Upgrade Wedbush Neutral → Outperform
Apr-12-19 Initiated Guggenheim Neutral
Feb-07-19 Upgrade Citigroup Sell → Buy
Feb-07-19 Downgrade Wedbush Outperform → Neutral
Feb-06-19 Upgrade Raymond James Underperform → Mkt Perform
Feb-04-19 Downgrade Citigroup Neutral → Sell
Dec-10-18 Downgrade Raymond James Outperform → Underperform
Sep-10-18 Resumed BTIG Research Buy
May-31-18 Initiated Evercore ISI Outperform
Mar-05-18 Initiated H.C. Wainwright Buy
Mar-31-17 Initiated Raymond James Outperform
View All

Macrogenics Inc Stock (MGNX) Latest News

pulisher
Aug 01, 2025

How strong is MacroGenics Inc. company’s balance sheetEntry Signal Growth Plan For Every Investor - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics LawsuitMGNX - ACCESS Newswire

Aug 01, 2025
pulisher
Jul 31, 2025

What institutional investors are buying MacroGenics Inc. stockPost Market Opportunities With High Returns - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

What makes MacroGenics Inc. stock price move sharplyOversold Recovery Opportunity Stocks Attract Buyers - beatles.ru

Jul 31, 2025
pulisher
Jul 31, 2025

MacroGenics’ Prostate Cancer Study: A Potential Game-Changer? - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

What are the latest earnings results for MacroGenics Inc.Best Dividend Ideas For Beginners - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 29, 2025

Why MacroGenics Inc. stock attracts strong analyst attentionTriple Digit Return Stock Predictions Released - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

MacroGenics’ Phase 2 Study: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

RSI and MACD Indicate Shift in MacroGenics Inc. SentimentProven Entry Plan With Low Risk Shared - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Is MacroGenics Inc. Starting a New UptrendBuy Low Sell High Stock Watch Strategy in Focus - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

MacroGenics’ Promising Study on Advanced Solid Tumors: Key Insights for Investors - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

Will MacroGenics Inc. see short term momentumWeekly Trend Watch with Market Signals - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

What the charts say about MacroGenics Inc. todayGrowth Summary Based on Market Positioning - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Analyzing MacroGenics Inc. with multi timeframe chartsFree Trend Following Strategy With Stop Loss - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is MacroGenics Inc. stock compared to the marketMarket Forecast Outlook With Proven Results - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is MacroGenics Inc. a growth stock or a value stockCapitalize on momentum-driven investment opportunities - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does MacroGenics Inc. generate profit in a changing economyAchieve breakthrough gains with expert advice - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What catalysts could drive MacroGenics Inc. stock higher in 2025Invest confidently with real-time market updates - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What is MacroGenics Inc. company’s growth strategyRealize consistent double-digit growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why is MacroGenics Inc. stock attracting strong analyst attentionAchieve rapid wealth accumulation with smart picks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

When is MacroGenics Inc. stock expected to show significant growthUnstoppable trading performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How MacroGenics Inc. stock performs during market volatilityProven Return Strategy Execution - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

Moving Average Trends for MacroGenics Inc. Stock: What They IndicateElite Stock Shortlist - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

MacroGenics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Access to Investment Community - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Is MacroGenics Inc. stock a good hedge against inflationFree Growth Investment Group - Newser

Jul 27, 2025
pulisher
Jul 25, 2025

MacroGenics Inc. Stock Analysis and ForecastTremendous financial leverage - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives MacroGenics Inc. stock priceExceptional earning trajectories - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about MacroGenics Inc. stockHigh-octane investment gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Is MacroGenics Inc. a good long term investmentMarket-crushing profits - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement - simplywall.st

Jul 24, 2025
pulisher
Jul 24, 2025

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of “Hold” by Brokerages - Defense World

Jul 24, 2025
pulisher
Jul 22, 2025

Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire

Jul 22, 2025

Macrogenics Inc Stock (MGNX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Cap:     |  Volume (24h):